Gout
📧 Sign up to get email alerts when something new happens for Gout.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2016-05-26Clinical Trial Update: Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat [Phase 3]
A Phase 3 clinical trial evaluating the combination of lesinurad and febuxostat for tophaceous gout has completed and posted results.
-
CLINICAL_TRIALS trial_result · 2016-05-26Clinical Trial Update: Combining Lesinurad With Allopurinol in Inadequate Responders [Phase 3]
Phase 3 trial evaluating adding lesinurad to allopurinol in gout patients inadequately responding to allopurinol; results were posted in 201…
-
CLINICAL_TRIALS trial_result · 2016-05-26Clinical Trial Update: Open-Label Lesinurad Monotherapy Extension Study in Gout [Phase 3]
An open-label extension study of lesinurad monotherapy for gout has completed Phase 3 research, with results posted in 2016.
-
CLINICAL_TRIALS research · 2016-05-17Clinical Trial Update: Meta-analyses of Total and Individual Fructose-containing Sugars and Incident Cardiometabolic Disease
This update summarizes meta-analyses examining total and individual fructose-containing sugars and their association with incident cardiomet…
-
CLINICAL_TRIALS research · 2016-05-17Clinical Trial Update: Meta-analyses of the Effect of Sucrose Versus High Fructose Corn Syrup on Cardiometabolic Risk
A meta-analysis update examining whether sucrose and high-fructose corn syrup have different effects on cardiometabolic risk factors.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2016-05-10FDA Approved: KRYSTEXXA — Supplemental Application (Horizon Therapeutics USA, Inc.)
The FDA approved a supplemental application for KRYSTEXXA (pegloticase) submitted by Horizon Therapeutics USA, expanding its approved labeli…
-
FDA approval · 2016-05-09FDA Approved: INDOMETHACIN — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approves Amneal's supplemental application for INDOMETHACIN, marking an approved modification to the product under an ANDA.
-
FDA approval · 2016-05-09FDA Approved: INDOMETHACIN — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' supplemental application for Indomethacin, resulting in updated labeling for the product.
-
FDA approval · 2016-05-09FDA Approved: NAPROXEN — Supplemental Application (Zameer Pharmaceuticals LLC)
FDA approved a supplemental application for Naproxen submitted by Zameer Pharmaceuticals LLC.
-
CLINICAL_TRIALS trial_result · 2016-04-27Clinical Trial Update: Food Effect Study of Febuxostat XR in Healthy Participants [Phase 1]
Phase 1 food-effect study of Febuxostat XR in healthy participants with results posted.
-
FDA approval · 2016-04-11FDA Approved: KRYSTEXXA — Supplemental Application (Horizon Therapeutics USA, Inc.)
The FDA approved a supplemental application for KRYSTEXXA (pegloticase) submitted by Horizon Therapeutics USA, Inc.
-
CLINICAL_TRIALS trial_result · 2016-03-31Clinical Trial Update: Extended Drug Utilization Study Among Patients Exposed to Ticagrelor, Clopidogrel and Prasugrel
This clinical trial update reports the completion of an extended drug utilization study evaluating adverse events among patients exposed to …
-
FDA approval · 2016-02-25FDA Approved: ALEVE GELCAPS — Supplemental Application (Bayer HealthCare LLC.)
The FDA approved a supplemental application to bring ALEVE GELCAPS (naproxen sodium) to market as a new dosage form from Bayer HealthCare LL…
-
FDA approval · 2016-02-12FDA Approved: ULORIC — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for ULORIC (febuxostat) from Takeda Pharmaceuticals America, Inc.
-
CLINICAL_TRIALS trial_result · 2016-02-12Clinical Trial Update: Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors [Phase 3]
Result update from a Phase 3 trial of lesinurad monotherapy in gout patients intolerant to xanthine oxidase inhibitors; the study has comple…
-
CLINICAL_TRIALS trial_result · 2016-02-03Clinical Trial Update: Safety and Efficacy of Oral Febuxostat in Subjects With Gout [Phase 3]
This is a Phase 3 trial assessing safety and efficacy of oral febuxostat in gout, with results posted.
-
FDA approval · 2016-01-25FDA Approved: COLCRYS — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved a supplemental application for COLCRYS (colchicine) filed by Takeda Pharmaceuticals America, expanding or updating the drug…
-
FDA approval · 2015-12-17FDA Approved: COLCRYS — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved a supplemental application for COLCRYS (colchicine) submitted by Takeda Pharmaceuticals America, Inc.
-
FDA approval · 2015-11-13FDA Approved: ALLOPURINOL — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved a supplemental application for Allopurinol from Actavis Pharma, Inc. (NDA018877).
-
CLINICAL_TRIALS trial_result · 2015-09-04Clinical Trial Update: Effects of Fasting on Self Efficacy
A completed clinical trial (NCT02113111) sponsored by Universität Duisburg-Essen evaluated the effects of fasting on self-efficacy across co…
-
FDA approval · 2015-08-24FDA Approved: NAPROXEN — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Naproxen by Hikma Pharmaceuticals USA Inc., indicating changes to the product's approval.
-
FDA approval · 2015-07-30FDA Approved: KRYSTEXXA — Supplemental Application (Horizon Therapeutics USA, Inc.)
The FDA approved a supplemental application for Krystexxa (pegloticase) from Horizon Therapeutics USA, Inc.
-
FDA approval · 2015-07-17FDA Approved: KRYSTEXXA — Supplemental Application (Horizon Therapeutics USA, Inc.)
The FDA approved a supplemental application for KRYSTEXXA (pegloticase) submitted by Horizon Therapeutics USA, Inc.
-
CLINICAL_TRIALS trial_result · 2015-07-01Clinical Trial Update: RDEA3170 Monotherapy in Subjects With Gout [Phase 2]
This update reports the completion of a Phase 2 monotherapy trial of RDEA3170 in subjects with gout.
-
CLINICAL_TRIALS trial_result · 2015-06-12Clinical Trial Update: A PD/Safety Study of RDEA3170 in Combination With Febuxostat for Treating Gout or Asymptomatic Hyperuricemia Patients [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating the combination of RDEA3170 with febuxostat for gout and asymptomatic hyperuricemia has completed.